Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharyngeal Immunity to Poliovirus Type-2 in Healthy bOPV- Versus IPV-vaccinated Infants
NCT05677256Phase 4Completed
- Sponsor
- Fighting Infectious Diseases in Emerging Countries
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of trivalent inactivated polio vaccine in poliomyelitis, sponsored by Fighting Infectious Diseases in Emerging Countries. Started Nov 2023; status: completed.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05677256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677256.